IDP 73152

Drug Profile

IDP 73152

Alternative Names: IDP-73152; IDP-73152 mesylate

Latest Information Update: 04 Apr 2016

Price : $50

At a glance

  • Originator Ildong Pharmaceutical
  • Class Antibacterials
  • Mechanism of Action Peptide deformylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Bacterial infections

Most Recent Events

  • 04 Apr 2016 Phase I development is ongoing in South Korea
  • 01 Jan 2014 Ildong Pharmaceutical completes a phase I trial in Healthy volunteers in South Korea (NCT01904318)
  • 31 Jul 2013 Phase-I clinical trials in Bacterial infections (in volunteers) in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top